Addex to Present at the Swiss Biotech Day 2024
April 19, 2024 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, April 19, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that...
FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
April 19, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung...
Nestlé announces retirement of Marco Settembri, appointment of Guillaume Le Cunff as CEO Zone Europe
April 18, 2024 13:00 ET
|
Nestlé S.A.
[Ad hoc announcement pursuant to Art. 53 LR] This press release is also available in Français (pdf) and Deutsch (pdf) ............. Nestlé announces retirement of Marco Settembri, appointment...
Generalversammlung 2024: Aktionäre von Tecan stimmen allen Anträgen des Verwaltungsrats zu
April 18, 2024 11:46 ET
|
Tecan Group AG
Generalversammlung 2024: Aktionäre von Tecan stimmen allen Anträgen des Verwaltungsrats zu Dividendenerhöhung von CHF 2.90 auf CHF 3.00 pro AktieMonica Manotas als zusätzliches unabhängiges Mitglied...
Annual General Meeting 2024: Tecan shareholders endorse all motions proposed by the Board of Directors
April 18, 2024 11:46 ET
|
Tecan Group AG
Annual General Meeting 2024: Tecan shareholders endorse all motions proposed by the Board of Directors Increase in the dividend from CHF 2.90 to CHF 3.00 per share Monica Manotas elected as...
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
April 18, 2024 01:00 ET
|
Addex Therapeutics
Top-line data from ADX71149 Phase 2 epilepsy study expected by mid-May 2024Launched Neurosterix with Perceptive Advisors, raising USD 63 million in Series A to accelerate development of preclinical...
Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting
April 17, 2024 11:12 ET
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS
April 17, 2024 02:00 ET
|
F. Hoffmann-La Roche Ltd
Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%)...
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
April 17, 2024 01:15 ET
|
Novartis Pharma AG
Continuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing multiple sclerosis (RMS) in an analysis...
Idorsia publishes a Financial Status required for an upcoming bondholder meeting
April 17, 2024 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Unaudited Financial Status as of March 31, 2024, required for an upcoming bondholder meeting, now available on the company websiteBondholder meeting now...